Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$26.85 USD
+0.71 (2.72%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $26.86 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TVTX 26.85 +0.71(2.72%)
Will TVTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
What Makes Travere (TVTX) a New Strong Buy Stock
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Other News for TVTX
Is TVTX consolidating before a move? NR7 shows up after dropping 0.23%
180 Bullish Setup appears for TVTX after 4.13% move
Is TVTX consolidating before a move? NR7 shows up after sinking 3.49%
TVTX forms Shooting Star Candlestick on October 9
TVTX forms 180 Bullish Setup on October 8